Navigation Links
RNA Nanotechnology To Rescue Cancer Patients In Future

Scientists have now developed tiny delivery vehicles that can carry anticancer therapeutic agents directly into infected cells, using strands of genetic material constructed through nanotechnology, offering a potential wealth // of new treatments for chronic diseases. This emerging branch of science is called nanomedicine.

These delivery agents are called nanoparticles, and are assembled from three short pieces of ribonucleic acid. The microscopic particles are designed in such a way that they possess both the right size to gain entry into cells and also the right structure to carry other therapeutic strands of RNA inside with them, where they are able to halt viral growth or cancer's progress.

RNA or ribonucleic acid has immense promise as a therapeutic agent against cancer, and furthermore, it might be possible to deliver multiple therapeutic agents to the cell at the same time, adding versatility and potential to the medical valve of the nanoparticles.

RNA molecules come in many variant forms, and the sort that the team mimicked from the phi29 virus – called pRNA – also can be linked to other types of RNA to form longer, hybrid strands with properties the researchers could assign. The nanoparticles have been created by linking together different kinds of RNA, after the successful manipulation of these stringy molecules into different shapes, including rods, triangles and arrays.

An effective agent against cancer needs to accomplish several tasks. It needs first to recognize the cancer cell and gain access to its interior, and then it needs to destroy it. It is also important for the molecule to act like a tracer that can provide valuable information regarding the location and the outcome of treatment.

Particles pass through cell membranes into the cell's interior, and the body has a hard time retaining particles smaller than 10 nanometers. But the tiny triangles fit, and they worked well enough to interrupt the grow
'"/>




Page: 1 2

Related medicine news :

1. CoQ10 bioavailability increased by Nanotechnology
2. Nanotechnology Revolution To Be Spearheaded By European Union
3. Scientists Consider About New Technology Called Nanotechnology
4. Potential Benefits Of New Nanotechnology
5. Nanotechnology Promises Huge Medical Benefits
6. Nanotechnology at its best: Nanomotors And Mechanical Nanoswitches
7. Nanotechnology Could Revolutionize Cardiac Treatment
8. Anti-Sense Drugs and Nanotechnology Offer New Hope In Cancer Fight
9. Nanotechnology – to detect and treat ovarian cance
10. Nanotechnology Used For Detecting Viruses
11. India, China Trying to Fight Disease With Nanotechnology
Post Your Comments:
(Date:12/5/2009)... debunks the ,something,s wrong with being single, myth , , SATURDAY, ... who pass their 40th birthday without ever tying the knot, ... woes than married folks. And, um, isn,t there something wrong ... fast. , A new study looking at psychological measures shows ...
(Date:12/4/2009)... Systems (NYSE: VAR ) announced today that its ... of Stockholders for February 11, 2010 with a record date ... the Crowne Plaza Cabana Hotel, 4290 El Camino Real, Palo ... be webcast by Thomson Financial and can be accessed at ...
(Date:12/4/2009)... The American Association of Homes and Services for the Aging ... Living and Supportive Services (CLASS) provisions remain in the final ... providing support to elders, people with disabilities and their caregivers. ... care reform bill that will make it affordable to care ...
(Date:12/4/2009)... While Congress debates whether health care reform ... point to 45 hospitals that lead through example ... nation while attaining the highest levels of efficiency. ... have been named 2009 Leapfrog Top Hospitals, based ...
(Date:12/4/2009)... Western Reserve University researchers, from the School of Medicine,s ... which products of lipid peroxidation and some drugs of ... identified by a combination of metabolomics and mass isotopomer ... of action of the drug of abuse gamma-hydroxybutyrate, also ...
Breaking Medicine News(10 mins):Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2
... the pharmaceutical Antifoam (Simethicone) business from Bluestar Silicones. , ... ... -- NuSil Technology ( http://www.nusil.com ), a leading formulator and ... announced a definitive agreement to acquire the pharmaceutical Antifoam (Simethicone) ...
... Sleep apnea has long been known to be associated with ... issue of Diabetes Care finds that the disorder ... nearly 87 percent of participants reported symptoms, but were ... doesn,t just mean their sleep is disrupted; existing research shows ...
... following is a statement of Matthew L. Myers, ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) The Campaign for Tobacco-Free ... his leadership role in Senate committee approval of ... Administration (FDA) regulatory authority over tobacco products, including ...
... Smart Balance, Inc. (Nasdaq: SMBL ) today held ... and CEO Stephen Hughes spoke to stockholders about the Company,s ... past year, consumers have found Smart Balance,s brand proposition compelling ... category of spreads," Hughes said. "We are excited as ...
... communities in outstate Minnesota MINNEAPOLIS, May 20 ... regional grants dedicated to reducing tobacco,s harm through ... grants will provide resources to communities outside the ... our continuing commitment to reducing tobacco,s harm and ...
... the Archdiocese of Boston may soon refer women ... Centene Corp. and archdiocese-run Caritas Christi Health Care.(Logo: ... over the impact of nationalized health care on ... to ethically compromise with a potential federal health ...
Other Medicine News:Health News:NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 2Health News:NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 3Health News:More than a bad night's sleep 2Health News:Sen. Tom Harkin Votes to Protect America's Kids From Tobacco 2Health News:Sen. Tom Harkin Votes to Protect America's Kids From Tobacco 3Health News:ClearWay Minnesota(SM) Board Approves Four Regional Grants 2Health News:ALL: Boston Archdiocese Reportedly on Track for Abortion Referring Venture 2
(Date:12/4/2009)... 4 Drs. Neal Shore and E. David Crawford ... additional analysis of secondary end points of biochemical recurrence ... (monthly degarelix for injection) or monthly leuprolide in prostate ... Prostate cancer patients who received FIRMAGON 240/80 mg/month had ...
(Date:12/3/2009)... YORK, Dec. 3 Guidepoint Global, LLC , a ... Sleep Apnea Tracker, a monthly longitudinal data release that monitors ... Apnea market. ,, The Sleep Apnea Tracker captures actual ... in the United States from 15 different equipment providers going ...
(Date:12/3/2009)... Calif., Dec. 3 Pharmacyclics, Inc. (Nasdaq: PCYC ... innovative small molecule drugs for the treatment of immune ... host a webcast and conference call on, Tuesday, December ... and 8:00am Pacific Time) to discuss clinical data regarding ...
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Smart Balance Announces 2009 Second Quarter Results 53838 1Smart Balance Announces 2009 Second Quarter Results 53838 2Smart Balance Announces 2009 Second Quarter Results 53838 3Smart Balance Announces 2009 Second Quarter Results 53838 4Smart Balance Announces 2009 Second Quarter Results 53838 5Smart Balance Announces 2009 Second Quarter Results 53838 6Smart Balance Announces 2009 Second Quarter Results 53838 7Smart Balance Announces 2009 Second Quarter Results 53838 8Smart Balance Announces 2009 Second Quarter Results 53838 9Smart Balance Announces 2009 Second Quarter Results 53838 10Living in U S May Raise Hispanics Cancer Risk 53835 1Living in U S May Raise Hispanics Cancer Risk 53835 2Living in U S May Raise Hispanics Cancer Risk 53835 3Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti Infection Treatments 13413 1Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti Infection Treatments 13413 2Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti Infection Treatments 13413 3
... This Patient ... Population -, ... and Bristol-Myers Squibb Company (NYSE: BMY ),announced today that the ... for ABILIFY(R) (aripiprazole) for the,acute treatment of manic and mixed episodes ...
... 275 residents screened for HIV during three testing days ... of,February, Test for Life worked with the Washington Wizards, ... Washington, DC,to offer free and confidential HIV testing to ... at the Temple of Praise,Whitman-Walker and Us Helping Us ...
Other Medicine Technology:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 2U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 3U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 4U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 5U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 6U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 7U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 8U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 9Test for Life Campaign Screens Record Number of DC Residents for HIV/AIDS 2
Adhesive discs sold on rolls of 100, 250, or 1000 each. Manufactured from non-latex medical grade adhesives & material. One size fits all chest pieces....
For accurately monitoring core temperature and heart and breath sounds....
... enables hospitals to standardize ... to a single temperature ... monitoring disposale probes and ... in their manufacture and ...
... Level 1 enables ... multiparameter patient monitors to ... series. Our temperature monitoring ... cables are superior in ...
Medicine Products: